Alpha Compute Corp · NASDAQ:ALP
Alpha Compute — Portage Biotech — Investor Presentation (May 2023)
24 slides from Alpha Compute's investor presentation, May 1, 2023
Slide 1: Corporate Presentation May 2023
1 Corporate Presentation Nasdaq: PRTG May 2023
Slide 2: Legal Disclaimer
2 Legal Disclaimer This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other author
Slide 3: Investment Highlights
3 Immuno - Oncology Company with Four First/Best in Class Compounds in the Clinic Investment Highlights Cost - Efficient Business Model, Potential Runway to Achieve Multiple Inflection Points Multiple Phase 1b/2 Data Catalysts in 2023 and 2024 Experienced Leadership Team from Bristol Myers Squibb
Slide 4: Proven Leadership with Oncology and Financing Expertise
4 Allan Shaw CFO Justin Fairchild VP Clin Dev Proven Leadership with Oncology and Financing Expertise Board of Directors Gregory Bailey, MD Rob Glassman, MD Linda M. Kozick Jim Mellon Mark Simon Ian Walters, MD CEO, Chairman Rob Kramer, PhD CSO Steve Innaimo VP PM & Operations Brian Wiley CBO Steven
Slide 5: Our Formula for Success
5 Our Formula for Success De - Risked Development Structured to Create Significant Value Strong Academic & Industry Network First/Best in Class I/O Agents Potential for Large Returns • Compounds with broad targets, single agent activity • Address ~70 - 80% of patients that don’t respond • Randomized
Slide 6: Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value
6 ASSET INDICATION STAGE # of PTS Interim Data Final Data ASSET INDICATION STAGE # of PTS Interim Data Final Data Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value iNKT Engager Platform SITC 2023 ASCO 2023 18 Phase 1 Melanoma + NSCLC PORT - 2 ESMO 2023 12 Phase 1 Solid Tumors PORT - 3 ASCO 2
Slide 7: iNKT Engagers PORT-2, PORT-3
iNKT Engagers PORT - 2, PORT - 3 Activating the innate, adaptive immune system and correcting the TME
Slide 8: Portage's iNKT Agonist (PORT-2): Liposomal Formulation of IMM60
8 Portage’s iNKT Agonist (PORT - 2): Rationally Designed Liposomal Formulation of IMM60 iNKT cell iNKT in charged liposome to protect lipid chain, aggregate in tumor, and promote Type 1 cytokine release IMM60 Binds to CD1d on APC and other myeloid cells TCR CD1d PORT 2 Immune activation
Slide 9: PORT-2 Stimulates Multiple Arms of the Immune System
9 Innate Immune System: Adaptive Immune System: Tumor Microenvironment: Kills cancer cells & increased PD - L1 expression iNKT cell PORT - 2 Stimulates Multiple Arms of the Immune System to Produce a Robust Anti - Cancer Response
Slide 10: Multiple Cell Types Needed for Anti-Cancer Response
10 Antigen MDSC & TAM CD - 8 T cell B - cell Dendritic cell NK cell Target cells Companies in the space PD - 1 PD - L1 Tumor Cell • Upregulates PD - L1 • Monotherapy activity in PD - 1 resistant models • Combo restores sensitivity to PD - 1 Ab + Enhanced activation Multiple Cell Types Needed for Ant
Slide 11: PORT-2 Demonstrates Robust Single Agent Activity
11 PORT - 2 Demonstrates Robust Single Agent Activity Jukes et al Eur. J. Immunol. 2016. 00: 1 – 11 IMM60 (0.5ng/mouse) PORT - 2 Vehicle + anti PD - 1 Vehicle Untreated PORT - 2 shows better response rates vs. anti - PD - 1 in melanoma model B16 melanoma lung metastases
Slide 12: SITC 2022 Interim Phase 1 Data Confirms PORT-2 Safety and MOA
12 SITC 2022 - Interim Phase 1 Data Confirms PORT - 2 Safety and MOA a Wennhold et al., Cancer Immunol Res 2021;9:1098 - 108. 2 Melanoma 4 NSCLC Tumor type 64 (41,79) Age 5(3,7) Median prior therapies 100% Prior PD - 1 50% ECOG 0 50% ECOG 1 Performance status • MCP - 1 ( Figure 3 ) and IP - 10 ( Fig
Slide 13: SITC 2022 Interim Phase 1 Data Confirms Activity
13 SITC 2022 - Interim Phase 1 Data Confirms Activity a Cancer Immunol Res 2021;9:1098 - 108. Evidence of monotherapy activity Baseline 3 months Mediastinal Lesion Decreased from 4cm to 1.9cm Additional data in 2023: • High dose cohort of patients receiving PORT - 2 monotherapy • total patients to r
Slide 14: IMPORT-201: Phase 2 Front Line NSCLC and Refractory Melanoma
14 Multi - arm study with four parallel development paths = multiple shots on goal IMPORT - 201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma https:// www.isrctn.com/ISRCTN80472712 PD - 1 q3wk iv infusions n=15 PD - 1 naïve patients PORT - 2 One dose @ MTD n=15 PORT - 2 + PD - 1 6 x iv
Slide 15: Adenosine Portfolio
Adenosine Portfolio Validated mechanism impacting multiple immune cells Opportunity to modulate adenosine in 4 different ways: PORT - 6 A2AR Inhibitor PORT - 7 A2BR Inhibitor PORT - 8 A2AR/A2BR Dual Inhibitor PORT - 9 Gut - Restricted A2BR Inhibitor
Slide 16: Leveraging A2A and A2B Alone or in Combo
16 Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment Targeting Adenosine in Cancer Immunotherapy to Enhance T - Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0 Macrophage Treg T cell NK Cell Endothelial Cell CAF MDSC
Slide 17: Difference in A2A Small Molecules
17 Difference in A2A Small Molecules 10+ hrs Only asset with single agent activity in mouse models Competitive inhibitors won’t block in settings of high adenosine ARCUS CORVUS Potency Selectivity 2.5 hrs Portage’s PORT - 6 is best in class for potency, selectivity and durability Relative profiles o
Slide 18: Fast Follower with Precedent for Biomarker Selection
18 Fast Follower with Precedent for Biomarker Selection * Expression data from Labcorp Probability of Survival 100 50 0 A 2A R low A 2A R h HR=0.45 (0.19 - 1 P=0.02 % A2A high* Tumor type 50 RCC 38 BC 34 NSCLC 32 Gastric 26 Prostate Best % Change in Tumor Lesion by High/ Low A 2A R levels Enrich pat
Slide 19: PORT-7: Highly Selective and Potent A2B Adenosine Receptor Antagonist
19 PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages • Activity in 4T1, CT26, and other disease models (asthma, fibrosis, sickle cell) Data on File Binding Affinity Functional Receptor Antagonism
Slide 20: ADPORT-601: Adaptive Phase 1a/1b Study
20 ADPORT - 601: Adaptive Phase 1a/1b Study Phase 1a Starting Dose (10 mg BID) (n=12 - 15) A2AR (PORT - 6) indications: A2BR (PORT - 7) indications: Colorectal Cancer, Non - small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer with high A2B expression Prostate Cancer, Non - small Cell Lung Can
Slide 21: Strong U.S. and Global IP Positions on Platforms and Products
21 iNKT Agonists • Composition, formulations with antigens, other I/O agents • Liposomes/particles 2031 - 2036 Patent Exclusivity Many Applications Pending Worldwide Strong U.S. and Global IP Positions on Platforms and Products Broad and deep intellectual property covering: >60 Issued Patents Adenos
Slide 22: Key Upcoming Clinical Development Milestones
22 Key Upcoming Clinical Development Milestones* 2023 2024 2025 Q1 Q2 Q3 Q4 1H 2H IMPORT - 201 (PORT - 2) P2 start IMPORT - 201 (PORT - 2) P2 ORR data ADPORT - 601 (Port - 6/7) study activation ADPORT - 601 (Port - 6/7) P1b start IMPORT - 201(PORT - 2) ASCO IMPORT - 201 (PORT - 2) SITC IMPORT - 201
Slide 23: Summary Financial Data
23 Summary Financial Data ~$13.1 million Cash Balance (12/31/22) $29.8 million Committed Purchase Lincoln Park Capital Available ^ $ - Debt 17,403,594 Shares Outstanding (03/01/23)** 50% Insider Ownership 50% Public Float* 1,596,040 Options & RSUs Outstanding (12/31/22) $(~2.0 million) Cash Burn Dur
Slide 24: Accelerating I/O Development in Untapped Growth Areas
24 Novel, Clinical Stage I/O Portfolio with Small Molecule Focus • Manufacturing simplicity, low capital investment • Nine phase 1b/2 clinical data reads over next 2 years Engine for Efficient Drug Development & Commercialization • Expert scientific oversight • Lean structure with financial flexibil